ATTAIN: Phase III study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC)

Tripathy, D, Tolaney, SM, Seidman, AD et al. (9 more authors) (2018) ATTAIN: Phase III study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC). In: Annals of Oncology. 43rd ESMO Congress (ESMO 2018), 19-23 Oct 2018, Munich, Germany. Oxford University Press .

Metadata

Authors/Creators:
  • Tripathy, D
  • Tolaney, SM
  • Seidman, AD
  • Anders, CK
  • Ibrahim, NK
  • Rugo, HS
  • Twelves, CJ
  • Dieras, V
  • Mueller, V
  • Hannah, AL
  • Tagliaferri, MA
  • Cortes Castan, J
Dates:
  • Published: October 2018
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cancer and Pathology (LICAP) > Clinical Cancer Research (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 11 Jul 2019 15:06
Last Modified: 11 Jul 2019 15:06
Status: Published
Publisher: Oxford University Press
Identification Number: https://doi.org/10.1093/annonc/mdy272.350
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics


CORE (COnnecting REpositories)